J&J's Weldon to get $143M in retirement

William C. Weldon, who oversaw Johnson & Johnson ($JNJ) during some of its most troubled years, will receive $143.5 million in retirement and deferred compensation after he relinquishes the CEO position, Bloomberg reports. In the last few years, J&J has had a raft of manufacturing problems at McNeil Consumer Health that led to the closing of a plant and the recall of products such as Tylenol. It has faced recalls and litigation over is hip implant products and a scandal over the marketing of its schizophrenia drug Risperdal. Just this week, reports said the Department of Justice had turned down a $1.3 billion settlement offer from J&J for its Risperdal problems because it wasn't enough. Story

Suggested Articles

Neopharma, which has been buying and building plants for several years, is buying a sterile injectables plant and assets in Japan from India’s Lupin. 

Already knocked by the FDA four times this year, Dr. Reddy’s now has a fifth Form 483 to dwell on. This time it’s at a plant with a history of faults.

In a warning letter, the FDA details how a Chinese OTC drugmaker handed over documents faked just for the agency's inspection—and admitted it.